stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) EPS (diluted)
Smith & Nephew SNATS, Inc.'s EPS (diluted) for fiscal 2025 was $1.43, up 52.3% from $0.94 in fiscal 2024. Over the past ten years it has ranged from $0.51 (fiscal 2022) to $1.76 (fiscal 2017); the current reading is higher than 73% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Smith & Nephew SNATS, Inc. ranks 26th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.43 | 52.34% |
| FY2024 | $0.94 | 56.67% |
| FY2023 | $0.60 | 17.65% |
| FY2022 | $0.51 | (57.50%) |
| FY2021 | $1.20 | 17.65% |
| FY2020 | $1.02 | (25.55%) |
| FY2019 | $1.37 | (9.27%) |
| FY2018 | $1.51 | (14.20%) |
| FY2017 | $1.76 | 0.00% |
| FY2016 | $1.76 | 91.30% |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| SNN Smith & Nephew SNATS, Inc. | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SNN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement